CORRECTION article

Front. Pharmacol., 31 August 2023

Sec. Pharmacogenetics and Pharmacogenomics

Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1274075

Corrigendum: CYP3A genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study

  • LM

    Laurence McEvoy 1*

  • JC

    Joanne Cliff 2

  • DF

    Daniel F Carr 1

  • AJ

    Andrea Jorgensen 3

  • RL

    Rosemary Lord 2

  • MP

    Munir Pirmohamed 1*

  • 1. Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom

  • 2. Clatterbridge Cancer Centre, Liverpool, United Kingdom

  • 3. Health Data Science, University of Liverpool, Liverpool, United Kingdom

Article metrics

View details

1,2k

Views

638

Downloads

In the published article, there was an error in the legend and artwork for Figure 2 as published. Additional information relating to variant carriage or non-carriage needed. Forest Plot data was incorrectly reported. The corrected Figure 2 and its caption appears below.

FIGURE 2

In the published article, there was an error. Meta-analysis data from Figure 2 was incorrectly reported in the Results.

A correction has been made to 3 Results, 3.4 Meta-analysis, paragraphs 2 and 3. These sentences previously stated:

“For CYP3A4*22, sufficient data was available from 2 studies (de Graan et al., 2013; Di Francia et al., 2017). Combining this with the data we generated showed that there was no association between CYP3A4*22 and PN (OR 1.1; 95% CI 0.62-1.97; I2 42%; p = 0.74).

For CYP3A5*3, sufficient data was available from 2 studies (Eckhoff et al., 2015a; Hu et al., 2016). Combining these two studies with the data from our candidate gene analysis again showed no association between CYP3A5*3 and PN (OR 0.99; 95% CI 0.57-1.71; I2 = 0%; p = 0.97).”

The corrected sentences appear below:

“For CYP3A4*22, sufficient data was available from 2 studies (de Graan et al., 2013; Di Francia et al., 2017). Combining this with the data we generated showed that there was no association between CYP3A4*22 and PN (OR 1.22; 95% CI 0.69–2.16; I2 55%; p = 0.49).

For CYP3A5*3, sufficient data was available from 2 studies (Eckhoff et al., 2015a; Hu et al., 2016). Combining these two studies with the data from our candidate gene analysis again showed no association between CYP3A5*3 and PN (OR 1.15; 95% CI 0.67–1.98; I2 = 0%; p = 0.61).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

chemotherapy, cytochrome P450, peripheral neuropathy, personalised medicine, pharmacogenetics

Citation

McEvoy L, Cliff J, Carr DF, Jorgensen A, Lord R and Pirmohamed M (2023) Corrigendum: CYP3A genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study. Front. Pharmacol. 14:1274075. doi: 10.3389/fphar.2023.1274075

Received

07 August 2023

Accepted

15 August 2023

Published

31 August 2023

Volume

14 - 2023

Edited and reviewed by

Luis Abel Quiñones, University of Chile, Chile

Updates

Copyright

*Correspondence: Laurence McEvoy, ; Munir Pirmohamed,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics